Medical Xpress

JANUARY 5, 2023

National Institutes of Health researchers have published an assessment of 13 studies that took a genotype-first approach to patient care. This approach contrasts with the typical phenotype-first approach to clinical research, which starts with clinical findings. The study was published in the American Journal of Human Genetics.

Genome 64

Genome Genomics Genetics Genotype 64

XTalks

NOVEMBER 10, 2020

For more information on tackling this “genomic analysis bottleneck,” watch this on-demand webinar. How many genes need to be scanned in order to determine the presence of a genetic disease? It also slows the progress of identifying new disease gene associations in very rare conditions.

Genome 98

Genome Genomics Medicine Genetic Disease 98

XTalks

APRIL 24, 2023

Awareness of rare diseases is growing, and with a better understanding of the pathophysiology of many rare diseases, innovative treatment options are emerging, like gene therapies that can treat the root cause of rare genetic diseases and potentially provide long-term symptom relief, or even a definitive cure.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

Worldwide Clinical Trials

DECEMBER 12, 2022

In some cases, the gene associated with a patient’s condition may not yet be discovered or included on the test ordered and the interpretation of genetic variants may change over time as new information is uncovered. single gene testing vs comprehensive panel), the reportable range (e.g.,

Clinical Trials 130

Clinical Trials Clinical Trials Genetics Trials 130

XTalks

APRIL 15, 2021

New advances in heart failure genomics are helping to address this challenge. Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. Watch this on-demand webinar to hear from these experts.

Development 98

Development Drugs Genomics Genome 98

Bioengineer

JANUARY 16, 2024

In patients with T790M mutant NSCLC receiving osimertinib, 63% experienced loss of T790M at progression, commonly linked to histological transdifferentiation, KRAS mutations, or gene fusions. not reached) in genomic analysis of post-progression samples from patients receiving second-line osimertinib. months vs. 15.2 months, p = 0.01).

Genomics 119

Genomics Genome Protein In-Vitro 119

pharmaphorum

JANUARY 24, 2023

The cost of testing per human genome in 2006 was approximately $14 million , and in less than two decades, an average consumer-purchased genetic test costs $100. The same is becoming true for the healthcare industry, and one of the first major breakthroughs in the area was the 100,000 Genomes Project.

Genetics 98

Genetics Drugs Genome Project Biobanking 98